Novan Conducts Guidance Meeting with FDA on SB204 Development Program
Sep 25, 2017 12:01 pm UTC| Business
MORRISVILLE, N.C., Sept. 25, 2017 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has concluded a guidance meeting with the U.S. Food and Drug Administration (FDA) regarding SB204 for the...
Sep 25, 2017 12:01 pm UTC| Business
NEW HAVEN, Conn., Sept. 25, 2017 -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that it will be making nine poster...
Sep 25, 2017 12:01 pm UTC| Business
PARSIPPANY, N.J., Sept. 25, 2017 -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and...
Sep 25, 2017 12:01 pm UTC| Business
REDWOOD CITY, Calif., Sept. 25, 2017 -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has...
Griffin Capital Securities Completes Channelization of Sales Organization
Sep 25, 2017 12:01 pm UTC| Business
EL SEGUNDO, Calif., Sept. 25, 2017 -- Griffin Capital Company, LLC (“Griffin Capital”) announced today that Griffin Capital Securities, LLC (“GCS”), Griffin Capital’s captive broker-dealer and distributor, completed a...
Atossa Genetics Announces Upcoming Phase 2 Study of Topical Endoxifen
Sep 25, 2017 12:01 pm UTC| Business
SEATTLE, Sept. 25, 2017 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions has contracted with...
Sep 25, 2017 12:01 pm UTC| Business
Protocol has been adjusted according to EMA Scientific AdviceFiling in Europe will be done in the coming days PARIS, Sept. 25, 2017 -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in...